top of page

Memory Studies

Our team pursues treatment studies designed to evaluate the effectiveness of investigational drugs in people with early memory loss as well as healthy individuals at risk of developing Alzheimer's disease.


Our team also conducts non-treatment research studies.  These trials contribute to our collective understanding of the Alzheimer's disease and often allow our patients to obtain an amyloid PET scan.

Treatment Studies

Aribio AR1001

A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 (an oral medication) in patients with mild to moderate Alzheimer's disease for 26 weeks.

AZ-Therapies COGNITE Study


AZ Therapies is studying safety and efficacy of a combination therapy medication, to determine whether it can slow the progression of symptoms in early Alzheimer’s disease.  Note: While we are still conducting this study, this study is closed for enrollment.

Memory Improvement Through Nicotine Dosing (MIND) Study 


The purpose of the study is to see if daily transdermal nicotine is able to produce a significant cognitive, clinical and functional improvement in participants with MCI. Neuronal nicotinic receptors have long been known to play a critical role in memory function in preclinical studies, with nicotine improving attention, learning, and memory function.  The study will enroll 300 participants for a 2 year period. Participants will be randomized (50:50) to either the transdermal nicotine, beginning at 7mg/day, and increasing to 21mg/day, or placebo skin patch.

Eisai's BAN2401 study for participants with early Alzheimer's Disease (Clarity AD)

This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer's disease (EAD).


Non-Treatment Studies 



The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition.  Amyloid PET scans are included as part of this study.  Note: While we are still participating in this trial, the study stopped enrolling new subjects as of October 9th 2017.

Please reload

bottom of page